CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited)

For the six months ended December 31, 2021

(Expressed in Canadian Dollars)

CONDENSED CONSOLIDATED INTERIM BALANCE SHEET

(Unaudited - Expressed in Canadian Dollars)

		 December 31	June 30
AS AT	Note	2021	2021
ASSETS			
Current			
Cash		\$ 799,277	\$ 672,365
Receivables		108,077	174,781
Sales tax receivable		94,797	118,395
Inventory	4	3,919,640	1,090,673
Prepaid expenses and inventory deposits	5	253,575	1,423,409
Total current assets		\$ 5,175,366	\$ 3,479,623
LIABILITIES Current Accounts payable and accrued liabilities	7	\$ 991,735	\$ 497,709
EQUITY			
Share capital	8	11,809,643	8,430,730
Reserves	8	2,073,093	878,006
Accumulated other comprehensive loss		1,578	(23,816)
Deficit		(9,700,683)	(6,303,006)
Total equity		4,183,631	2,981,914
Total liabilities and equity		\$ 5,175,366	\$ 3,479,623

Nature and continuance of operations (Note 1) Commitments and contingencies (Note 14) Subsequent event (Note 15)

Approved on behalf of the Board of Directors and authorized for issuance on February 28, 2022:

"Warren Spence"	"Scott Eldridge"
Warren Spence, Director	Scott Eldridge, Director

CONDENSED CONSOLIDATED INTERIM STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited - Expressed in Canadian Dollars)

			Three months ended			Six months e	nded
	Note		December 31,	December 31,		December 31,	December 31,
	Note		2021	2020		2021	2020
Devenue		\$	07 001 ¢		۲.	140.152 6	
Revenue		Ş	97,881 \$	-	\$	149,152 \$	-
Cost of goods sold			114,817		_	177,659	
Gross margin			(16,936)	-	_	(28,507)	
Expenses							
General and administrative			100,766	93,061		187,758	108,374
Marketing and promotion			355,312	197,853		1,036,149	481,604
Consulting	10		756,132	186,400		1,567,794	575,311
Professional fees			97,017	116,963		164,796	127,829
Share-based compensation	8 & 10		258,695	158,411		412,673	158,897
Total expenses			1,567,922	752,688		3,369,170	1,452,015
Net loss			(1,584,858)	(752,688)		(3,397,677)	(1,452,015)
Other comprehensive (loss) income							
Foreign currency translation gain			28,143	(18,667)		(25,394)	(16,807)
Total other comprehensive income			28,143	(18,667)		(25,394)	(16,807)
Net and comprehensive loss		\$	(1,556,715) \$	(771,355)	\$	(3,423,071) \$	(1,468,822)
Loss per share							
Basic and diluted		\$	(0.02) \$	(0.02)	\$	(0.05) \$	(0.05)
Weighted average number of common sh	ares						
Basic and diluted			72,132,347	35,513,804		68,762,755	32,136,540

RRITUAL SUPERFOODS INC.

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited - Expressed in Canadian Dollars)

		Number of			Share		Equity Portion		Accumulated Other		
	Note	common shares	Sharo	Capital	subscriptions received	receivable	of Convertible Notes	Reserves	Comprehensiv e Loss	Deficit	Total equity
	Note	Silaies	Silare	Capital \$	receiveu	receivable \$	Notes	keserves \$	e Loss \$	belicit \$	
				<u>\$</u>	\$	Ş	<u> </u>	\$	\$	Ş	\$
Balance, June 30, 2020		20,250,200	\$ 3	96,252	\$ 13,000	(20,000)	\$ -	\$ 20,376	\$ -	(161,316) \$	248,312
Common shares issued for cash		12,275,000	9	51,500	(13,000)	20,000	-	-	-	-	958,500
Share issuance costs		-	(69,169)	-	-	-	-	-	-	(69,169)
Common shares issued for services		1,380,000	1	38,000	-	-	-	-	-	-	138,000
Common shares issued for asset acquisition		1,500,000		30,000	-	-	-	-	-	-	30,000
Cancellation of common shares		(200)		(8)	-	-	-	-	-	8	-
Exercise of options		375,000		39,151	-	-	-	(1,651)	-	-	37,500
Issuance of convertible promissory notes		-		-	-	-	950,402	-	-	-	950,402
Share-based compensation		-		-	-	-	-	158,897	-	-	158,897
Net loss and other comprehensive loss		-		-	-	-	-	-	(16,807)	(1,452,015)	(1,468,822)
Balance, December 31, 2020		35,780,000	\$ 1,4	85,726	-	-	950,402	177,622	(16,807)	(1,613,323) \$	983,620
Balance, June 30, 2021		62,227,347		30,730	-	-	-	878,006	(23,816)	(6,303,006) \$	2,981,914
Common shares issued for cash	8	8,000,000	,	.60,000	-	-	-	840,000	-	-	4,000,000
Share issue costs - cash	8	-	•	21,423)	-	-	-	-	-	-	(421,423)
Share issue costs - fair value of broker warrants	8	-	,	62,273)	-	-	-	62,273	-	-	-
Exercise of options		1,830,000		68,859	-	-	-	(119,859)	-	-	549,000
Exercise of warrants		75,000		33,750	-	-	-	-	-	-	33,750
Share-based compensation		-		-	-	-	-	412,673	-	-	412,673
Translation adjustment		-		-	-	-	-	-	25,394	-	25,394
Net loss for the period		-			-	-	-	-	-	(3,397,677)	(3,397,677)
Balance, December 31, 2021		72,132,347	\$ 11,8	09,643	-	-	-	2,073,093	1,578	(9,700,683) \$	4,183,631

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS

(Unaudited - Expressed in Canadian Dollars)

	Six months ended		Six months ended		
	Dec	ember 31, 2021	Dec	ember 31, 2020	
Operating activities					
Net loss for the period	\$	(3,397,677)	\$	(1,452,015)	
Adjusted for:	*	(5,551,511,	т	(=, :==,===,	
Share-based compensation		412,673		158,897	
Shares issued for service		-		138,000	
Changes in non-cash working capital:				,	
Accounts receivable		67,266		-	
Sales tax receivable		23,598		(48,495	
Inventory		(2,805,161)		(47,683	
Prepaid expenses and deposits		1,169,854		(617,199	
Deferred financing costs		-		(74,777	
Accounts payable and accrued liabilities		489,342		136,679	
Cash flows - operating activities		(4,040,105)		(1,806,593)	
Investing activities Trademark purchases Cash flows - investment activities Financing activities		<u>-</u>		(3,950 [°]	
Common shares issued for cash		4,000,000		926,831	
Share issue costs		(421,423)		-	
Common shares issued on exercise of options and warrants		582,750		-	
Convertible notes issued		, -		950,402	
Cash flows - financing activities		4,161,327		1,877,233	
Effect of foreign exchange on cash		5,690		(7,616	
Change in cash		126,912		59,074	
Cash, beginning of year		672,365		321,270	
Cash, end of period	\$	799,277	\$	380,344	
Supplemental cash flow disclosure:					
Fair value of broker warrants	\$	62,273		_	
Residual value of bought deal warrants	\$	840,000		_	
nestada value of bought dear wallalls	Ą	040,000			

No cash was paid for interest or income taxes for the periods presented.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months ended December 31, 2021

(Unaudited - Expressed in Canadian Dollars)

1. NATURE AND CONTINUANCE OF OPERATIONS

Rritual Superfoods Inc. (the "Company") was incorporated pursuant to the provisions of the British Columbia Business Corporations Act as 1207645 BC Ltd. on May 6, 2019. On April 3, 2020, it changed its name to Rritual Mushrooms Inc and on November 5, 2020, it changed its name to Rritual Superfoods Inc. The Company's registered and records office address is 900 – 855 West Georgia Street, Vancouver, BC, V6C 3H1. The Company's head office address is 151 West Hasting Street, Vancouver BC, V6B 1H4.

The Company is engaged in the business of development, marketing, sales, and distribution of proprietary dietary and nutritional supplements and beverages containing herbs and other extracts such as fruits, roots, fungi, and vegetables. The Company's initial product launches are focused on plant-based products incorporating mushroom based adaptogens. The Company sells its suite of products through an omni-channel business strategy direct to consumer and, through distribution partners, to brick-and-mortar retailers.

On February 26, 2021, the Company completed its initial public offering (the "IPO") of 20,000,000 units. Each unit consisted of one common share and one-half share purchase warrant. The Company listed its common shares on the CSE effective March 5, 2021, under the trading symbol RSF. The IPO warrants are listed on the CSE under the trading symbol RSF-WT.

These condensed consolidated interim financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation. The financial statements do not include adjustments to amounts and classifications of assets and liabilities that might be necessary should the Company be unable to continue operations. The Company has incurred a net loss of \$3,397,677 for the six months ended December 31, 2021, and the Company's ability to continue as a going concern is dependent upon its ability in the future to achieve profitable operations and, obtain the necessary financing to meet its near-term obligations such that it can repay its liabilities when they become due. The inability to achieve these objectives may cast significant doubt about the Company's ability to continue as a going concern.

On March 11, 2020, the World Health Organization categorized COVID-19 as a pandemic. The potential economic effects within the Company's environment and in the global markets, possible disruption in supply chains, and measures being introduced at various levels of government to curtail the spread of the virus (such as travel restrictions, closures of non-essential municipal and private operations, imposition of quarantines and social distancing) could have a material impact on the Company's operations. As of November 26, 2021, the extent of the impact of this outbreak and related containment measures on the Company's operations cannot be reliably estimated.

2. BASIS OF PRESENTATION, USE OF ESTIMATES, ASSUMPTIONS, AND JUDGEMENTS

Statement of compliance

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") in accordance with International Accounting Standards 34, "Interim Financial Reporting" ("IAS 34") as issued by the International Accounting Standards Board ("IASB"), and interpretations of the IFRS Interpretations Committee ("IFRIC").

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Six months ended December 31, 2021

(Unaudited - Expressed in Canadian Dollars)

2. BASIS OF PRESENTATION (Continued)

Basis of measurement

These consolidated financial statements have been prepared on a historical cost basis, except for financial instruments classified as financial instruments at fair value through profit or loss, which are stated at fair value. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting except for cash flow information.

Use of estimates, assumptions, and Judgements

The preparation of financial statements in conformity with IFRS requires the use of judgments and/or estimates that affect the amounts reported and disclosed in these consolidated financial statements and related notes. These judgments and estimates are based on management's best knowledge of the relevant facts and circumstances, having given regard to previous experience, but actual results may differ materially from the amounts included in the financial statements.

Share-based payments

The Company utilizes the Black-Scholes Option Pricing Model ("Black-Scholes") to estimate the fair value of warrants and stock options granted to directors, officers, employees, consultants. The use of Black-Scholes requires management to make various estimates and assumptions that impact the value assigned to the stock options including the forecast future volatility of the stock price, the risk-free interest rate, dividend yield and the expected life of the stock options. Any changes in these assumptions could have a material impact on the Share-based compensation calculation value, however the most significant estimate is volatility. The Company estimated volatility based on historic share prices of companies operating in the regulated cannabis industry as it presented a reasonable analogy of an emerging consumer product segment. Historical volatility is not necessarily indicative of future volatility.

The Performance Share Units ("PSUs") include the use of an estimate that revenue milestones are achieved by a specified date, which can affect the fair value estimate.

Presentation and functional currency

The consolidated financial statements of the Company are presented in Canadian dollars.

The functional currency of the Company is the Canadian dollar. The functional currency of the Company's wholly owned subsidiary is detailed below.

		Country of	Percentage	Functional	
Name of subsidiary	Abbreviation	Incorporation	Ownership	Currency	Principal Activity
Rritual USA Inc.	Rritual USA	USA	100%	USD	Dietary Supplements

Carrying value of inventory

The Company records valuation adjustments for inventory by comparing the inventory cost to its net realizable value. The process requires the use of estimates and assumptions related to future market demand, costs and prices. Such assumptions are reviewed and may have a significant impact on the valuation adjustments for inventory.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months ended December 31, 2021 (Unaudited - Expressed in Canadian Dollars)

3. SIGNIFICANT ACCOUNTING POLICIES

Consolidation

These consolidated financial statements include the accounts of the Company and its subsidiary, which is controlled by the Company. Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. All intercompany transactions are eliminated upon the preparation of these consolidated financial statements.

Foreign currencies

Functional and presentation currency

The functional currency is the currency of the primary economic environment in which the entity operates. The functional currency of the Company and its subsidiary was determined by conducting an analysis of the consideration factors identified in IAS 21, "The Effects of Changes in Foreign Exchange Rates" ("IAS 21"). The functional currency of the Company and its subsidiary is included within Note 2.

Translation of foreign transactions and balances into the functional currency

Foreign currency transactions are translated into the functional currency of the Company at rates of exchange prevailing on the dates of the transactions. At each reporting date, all monetary assets and liabilities that are denominated in foreign currencies are translated to the functional currency of the Company at the rates prevailing at the date of the statement of financial position. Foreign exchange gains and losses resulting from the settlement of such transactions are recognized in profit or loss.

Translation of the functional currency into the presentation currency

The results of operations which have a different presentation currency than the Company are translated to Canadian dollars at appropriate average rates of exchange during the period. The assets and liabilities of these operations are translated to Canadian dollars at rates of exchange in effect at the end of the period. Gains or losses arising on translation of these operations to Canadian dollars at period end are recognized in accumulated other comprehensive income as a translation adjustment.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months ended December 31, 2021 (Unaudited - Expressed in Canadian Dollars)

Share-based payments

The Company makes periodic grants of share-based awards to selected directors, officers, employees and others providing similar service under the Company's omnibus long-term incentive plan ("LTIP").

Pursuant to the Company's LTIP the fair value of the equity-settled awards is determined at the date of the grant by using the Black-Scholes Option Pricing Model. At each reporting date prior to vesting, the cumulative expense representing the extent to which the vesting period has expired and management's best estimate of the awards that are ultimately expected to vest is computed. The movement in cumulative expense is recognized in the consolidated statement of operations and loss with a corresponding entry within equity, against the reserve for equity settled share-based transactions. No expense is recognized for awards that do not ultimately vest.

In situations where equity instruments are issued to non-employees and some or all of the goods or services received by the entity as consideration cannot be specifically identified, they are measured at fair value of the share-based payment. Otherwise, share-based payments are measured at the fair value of goods or services received.

The Company has other share-based compensation plans in the form of Deferred Share Units ("DSUs"), Restricted Share Units ("RSUs") and Performance Share Units ("PSUs"). Units granted under these share-based compensation plans are recorded at fair value on the grant date and are adjusted for changes in fair value each reporting period until settled. The expense, and any changes which arise from fluctuations in the fair value of the grants, is recognized in share-based compensation in the consolidated statement of operations and loss.

Income taxes

Income tax on the profit or loss for the periods presented comprises current and deferred tax. Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax expense is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at period end, adjusted for amendments to tax payable with regards to previous years.

Deferred tax is recorded by providing for temporary differences, between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: goodwill not deductible for tax purposes; the initial recognition of assets or liabilities which affect neither accounting nor taxable loss as well as differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the consolidated statement of financial position date.

A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized.

Additional income taxes that arise from the distribution of dividends are recognized at the same time as the liability to pay the related dividend. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months ended December 31, 2021 (Unaudited - Expressed in Canadian Dollars)

3. ACCOUNTING POLICIES (Continued)

Loss per share

The Company presents basic loss per share for its common shares, calculated by dividing the loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the six months ended December 31, 2021. Diluted loss per share does not adjust the loss attributable to common shareholders or the weighted average number of common shares outstanding when the effect is anti-dilutive.

Financial instruments

Financial assets

On initial recognition, financial assets are recognized at fair value and are subsequently classified and measured at: (i) amortized cost; (ii) fair value through other comprehensive income ("FVOCI"); or (iii) fair value through profit or loss ("FVTPL"). The classification of financial assets is generally based on the business model in which a financial asset is managed and its contractual cash flow characteristics. A financial asset is measured at fair value net of transaction costs that are directly attributable to its acquisition except for financial assets at FVTPL where transaction costs are expensed. All financial assets not classified and measured at amortized cost or FVOCI, are measured at FVTPL. On initial recognition of an equity instrument that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment's fair value in other comprehensive income.

The classification determines the method by which the financial assets are carried on the statement of financial position subsequent to inception and how changes in value are recorded. Cash is classified on the statement of financial position at FVTPL. Receivables are recorded on an amortized cost basis.

<u>Impairment</u>

An 'expected credit loss' impairment model applies which requires a loss allowance to be recognized based on expected credit losses. The estimated present value of future cash flows associated with the asset is determined and an impairment loss is recognized for the difference between this amount and the carrying amount as follows: the carrying amount of the asset is reduced to estimated present value of the future cash flows associated with the asset, discounted at the financial asset's original effective interest rate, either directly or through the use of an allowance account and the resulting loss is recognized in profit or loss for the period.

In a subsequent period, if the amount of the impairment loss related to financial assets measured at amortized cost decreases, the previously recognized impairment loss is reversed through profit or loss to the extent that the carrying amount of the investment at the date the impairment is reversed does not exceed what the amortized cost would have been had the impairment not been recognized.

Financial liabilities

Financial liabilities are designated as either: (i) FVTPL; or (ii) other financial liabilities. All financial liabilities are classified and subsequently measured at amortized cost except for financial liabilities at FVTPL. The classification determines the method by which the financial liabilities are carried on the statement of financial position subsequent to inception and how changes in value are recorded. Accounts payable and accrued liabilities is classified on the statement of financial position at amortized cost.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months ended December 31, 2021 (Unaudited - Expressed in Canadian Dollars)

3. ACCOUNTING POLICIES (Continued)

Share capital

Common shares are classified as shareholders' equity. Incremental costs directly attributable to the issue of common shares and other equity instruments are recognized as a deduction from shareholders' equity. Common shares issued for consideration other than cash, are valued based on their market value at the date the shares are issued.

The Company has adopted a residual value method with respect to the measurement of warrants attached to private placement units. The residual value method first allocates value to the more easily measurable component based on fair value and then the residual value, if any, to the less easily measurable component. The Company considers the fair value of common shares issued in the private placements to be the more easily measurable component and the common shares are valued at their fair value, as determined by the closing market price on the announcement date. The balance, if any, is allocated to the attached warrants. Any fair value attributed to the warrants is recorded as reserves.

Intangible Assets

Other intangible assets, comprising product formulations that are acquired by the Company and have finite useful lives are measured at cost less accumulated amortization and any accumulated impairment losses. Amortization is calculated to write off the cost of intangible assets less their estimated residual values using the straight-line method over the estimated useful lives and is recognized in profit or loss. The amortization of product formulations begins when the Company starts to generate revenue from the asset. Acquired formulations are amortized on a straight-line basis over a period of one year.

Amortization methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

Inventory

The Company defines inventory as all purchased raw materials and finished goods for resale, consumable supplies, and accessories.

Raw materials and finished goods are initially recognized at cost and subsequently valued at the lower of average cost and net realizable value ("NRV"). The Company reviews for obsolescence, redundancy and slow turnover and any such inventory are written down to net realizable value.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months ended December 31, 2021 (Unaudited - Expressed in Canadian Dollars)

3. ACCOUNTING POLICIES (Continued)

Revenue

The Company's accounting policy for revenue recognition under IFRS 15 is as follows:

To determine the amount and timing of revenue to be recognized, the Company follows a 5-step process:

- 1. Identifying the contract with a customer
- 2. Identifying the performance obligations
- 3. Determining the transaction price
- 4. Allocating the transaction price to the performance obligations
- 5. Recognizing revenue when/as performance obligation(s) are satisfied.

Revenue from the sale of dietary supplements is recognized when the risks and rewards of the products have been substantially transferred to the customer (usually on delivery of the goods), which is the Corporation's sole performance obligation. The Corporation to date has experienced few product returns and, accordingly, records an estimated 5% provision obligation for estimated returns. Collection of the Corporation's invoices typically occurs within 90 days of the sale.

Marketing programs provided to customers and operators, including volume rebates, cooperative advertising and other trade marketing programs, are all customer-specific programs to promote the Company's products. Consequently, sales are recorded net of these estimated marketing costs at the time of sale. All other non-customer-specific marketing costs (general advertising, etc.) are expensed as incurred as selling, general and administrative expenses.

Certain customers require payment of one-time listing allowances (or "product listing fees") to obtain space for a new product in their stores. These fees are considered incremental costs of obtaining a contract and, if recovery is expected through sales to the customer in future periods, are capitalized as product listing fees (included in prepaid expenses and deferred costs) and amortized to contra-revenue over the estimated recovery period. Product listing fees that are insignificant or are not estimated to have future economic benefit are recorded to contra-revenue in the period incurred.

New accounting policies

The Company has not yet adopted certain standards, interpretations to existing standards and amendments which have been issued but have an effective date later than July 1, 2021. Many of these updates are not currently relevant to the Company and are therefore not discussed herein.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Six months ended December 31, 2021

(Unaudited - Expressed in Canadian Dollars)

4. INVENTORY

	December 31 2021	December 31 2021		
Raw materials	\$ 1,944,555	\$	80,350	
Finished goods	1,975,085		1,010,323	
otal	\$ 3,919,640	\$	1,090,673	

During the six months ended December 31, 2021, inventory expensed to cost of goods sold was \$Nil (2021 - \$Nil).

5. PREPAID EXPENSES AND INVENTORY DEPOSITS

	De	cember 31	June 30,	
		2021	2021	
Prepaid expenses	\$	250,356	\$ 745,928	
Deposits for inventory		3,219	677,481	
Total	\$	253,575	\$ 1,423,409	

During the year ended June 30, 2021, the Company issued \$748,000 in RSU's which vested on grant for consulting services which are recorded as prepaid expenses and amortized over the life of the consulting contracts. During the six months ended December 31, 2021, the Company recognized \$377,074 (2020 - \$176,241) in related consulting services.

6. INTANGIBLE ASSETS

The following is a continuity schedule of intangible assets:

	Dec	ember 31	June 30,
		2021	2021
Opening Balance	\$	-	\$ -
Additions - product formulations		-	30,000
Amortization		-	(30,000)
Balance, December 31, 2021	\$	-	\$ -

7. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	Dec	December 31 2021		June 30, 2021	
Accounts payable	\$	987,046	\$	434,236	
Accrued liabilities		4,689		63,473	
tal	\$	991,735	\$	497,709	

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months ended December 31, 2021

(Unaudited - Expressed in Canadian Dollars)

8. SHARE CAPITAL AND RESERVES

Authorized

Unlimited common shares with no par value. As of December 31, 2021, there were 72,132,347 common shares outstanding.

Escrow shares

The Company has shares subject to trading restrictions and escrow which are released in tranches through 2022. As of December 31, 2021, a total of 16,409,167 common shares were subject to these escrow restrictions.

<u>Issued and Outstanding – Common Shares Fiscal 2022:</u>

During the six months ended December 31, 2021, the Company issued common shares as follows:

- a) The Company has closed its \$4,000,000 "bought deal" public offering (the "Offering") with net proceeds of \$3,578,577. The Offering was underwritten by Clarus Securities Inc. (the "Underwriter"). Each Unit consists of one common share of Rritual (a "Common Share") and one-half Common Share purchase warrant. Each whole warrant (a "Warrant") entitles the holder to purchase one Common Share of Rritual at a price of \$0.60 per Common Share until March 5, 2024, subject to an acceleration provision. Pursuant to the Offering, Rritual issued an aggregate of 8,000,000 Units at a price of \$0.50 per Unit, for total gross proceeds of \$4,000,000. The gross proceeds were allocated to shares and warrants on the basis of \$0.395 per share and \$0.105 per whole Warrant based on the terms of the over-allotment option. Pursuant to the terms of an agreement with the underwriters, ("Underwriters"), the Company paid a cash commission of \$240,000 and issued 480,000 brokers warrants with an exercise price of \$0.60 and a term of two years. The broker warrants were valued at \$62,273 based on the following Black Scholes assumptions: 0% dividend yield, 80% expected volatility, 0.92% expected interest and a 2-year expected life. The Company also incurred cash share issuance costs of \$199,601 in connection with this offering.
- b) 1,830,000 common shares were issued pursuant to the exercise of stock options for gross proceeds of \$549,000. In relation to the exercises of stock options the Company reallocated \$119,859 from reserves to share capital.
- c) 75,000 common shares were issued pursuant to the exercise of warrant options for gross proceeds of \$33,750.

<u>Issued and Outstanding – Common Shares Fiscal 2021:</u>

During the year ended June 30, 2021, the Company issued common shares as follows:

- a) The Company completed a private placement of 3,450,000 common shares at a price of \$0.02 per share for gross proceeds of \$69,000.
- b) The Company issued 1,500,000 common shares of the Company at a price of \$0.02 per share pursuant to an asset purchase agreement to acquire product formulations for an aggregate fair value of \$30,000. Of the 1,500,000 shares issued, 1,375,000 were issued to directors of the Company.
- c) The Company completed a private placement of 8,825,000 units at a price of \$0.10 per unit for gross proceeds of \$882,500. Each unit consists of one common share and one-half common share purchase warrant exercisable at a price of \$0.45 for a period of two years from closing. The Company incurred share issuance costs of \$69,169 in relation to the private placement.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months ended December 31, 2021

(Unaudited - Expressed in Canadian Dollars)

8. SHARE CAPITAL AND RESERVES (Continued)

Issued and Outstanding - Common Shares Fiscal 2021 (Continued):

- d) The Company issued 1,380,000 common shares for services at a fair value of \$0.10 per share for total consideration of \$138,000. Of the shares issued 1,300,000 were issued to directors and officers of the Company.
- e) The Company issued 755,000 common shares pursuant to the exercise of options in exchange for consideration of \$139,000 and the reallocation of \$23,750 of reserves from previously recognized share-based compensation expense.
- f) The Company cancelled 200 common shares. In relation to the cancellation the Company recorded a charge to deficit of \$8.
- g) On February 26, 2021, the Company completed its initial public offering (the "IPO") of 20,000,000 units at a price of \$0.30 per unit for gross proceeds of \$6,000,000. Each unit consisted of one common share and one-half share purchase warrant with each full warrant being exercisable at price of \$0.60 for a period of thirty-six months. The Company paid cash commission equal to 7% of the aggregate gross proceeds of \$420,000 and incurred share issue costs \$343,684 for total cash-based share issuance costs of \$763,684. The Co-lead underwriters were granted 1,400,000 broker warrants exercisable into units at a price of \$0.30 expiring March 5, 2024. Each broker warrant unit consists of one common share and one-half common share purchase warrant with each full warrant exercisable at \$0.60 expiring March 5, 2024. The grant date fair value of the broker warrants was \$216,398 using the Black-Scholes valuation model with the following assumptions: expected life 3 years; volatility 80%; dividend yield of 0%; and risk-free rate 0.5%. The Company also issued 1,000,000 corporate finance fee units at a value of \$0.30 which was recorded as non-cash share issue cost totaling \$300,000. Each corporate finance fee unit consists of one common share and one-half common share purchase warrant with each full warrant (500,000 in aggregate) exercisable at a price of \$0.60 per share expiring March 5, 2024.
- h) On April 5, 2021, the Company granted an aggregate of 1,140,000 RSUs to certain consultants, directors, and officers of the Company pursuant to the Plan. Each RSU represents the right to receive, once vested, one common share in the capital of the Company. All of the RSUs granted to consultants of the Company vested immediately upon grant and all of the RSUs granted to directors and officers of the Company will vest on January 1, 2022.
- i) On April 5, 2021, amended the vesting of 720,000 RSUs which were to vest between April 1, 2021, and January 1, 2022, to vest fully on April 5, 2021.
- j) On April 5, 2021, 1,750,000 common shares were issued pursuant to the conversion of RSUs.
- k) 134,264 common shares were issued pursuant to the exercise of warrants for gross proceeds of \$80,558.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Six months ended December 31, 2021

(Unaudited - Expressed in Canadian Dollars)

8. SHARE CAPITAL AND RESERVES (Continued)

Stock options

The Company has adopted a long-term incentive plan (the "Plan") for its directors, officers, employees, and consultants to acquire common shares of the Company. The plan provides a framework for the Company to grant Stock Options, Restricted Share Units, Performance Share Units, and Deferred Share Units. The aggregate number of Stock options and Units granted shall not exceed 25% of the issued and outstanding common shares of the Company with no one individual director or officer being granted options or units to acquire more than 10% of the issued and outstanding common shares. In addition, the exercise price of stock options granted under the plan shall not be lower than the market price on the date of grant. The maximum term of an option award under the plan is 10 years.

A summary of stock option activity is as follows:

	Number of	Weighted Average
	Options	Exercise Price \$
Balance at June 30, 2020	5,300,000	0.10
Cancelled	(1,750,000)	0.14
Exercised	(755,000)	0.18
Granted	4,500,000	0.35
Balance at June 30, 2021	7,295,000	0.28
Exercised	(1,830,000)	0.30
Granted	4,200,000	0.35
Balance at December 31, 2021	9,665,000	0.31

The following table summarizes stock options outstanding and exercisable as of December 31, 2021:

	Number of	Number of		Weighted Average
Expiry date	Options	Exercisable Options	Weighted Average	Remaining Years
June 23, 2025	1,812,500	1,812,500	0.10	3.48
June 23, 2025	300,000	300,000	0.30	3.48
October 8, 2025	1,370,000	1,370,000	0.30	3.77
November 24, 2025	445,000	445,000	0.30	3.90
February 1, 2026	512,500	384,375	0.30	4.09
March 8, 2026	1,025,000	768,750	0.54	4.19
November 8, 2026	4,200,000	400,000	0.35	4.86
	9,665,000	5,480,625	0.31	4.25

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Six months ended December 31, 2021

(Unaudited - Expressed in Canadian Dollars)

8. SHARE CAPITAL AND RESERVES (Continued)

Share-based compensation expense recognized during the six months of \$213,950 related to options vested during the six months ended December 31, 2021. The Option Pricing Model used the following weighted average assumptions:

	December 31	June 30,
	2021	2021
Risk-free interest rate	0.50%	0.50%
Expected life of options	4	4
Expected forfeitures	10%	10%
Annualized volatility	80%	80%
Dividend rate	0%	0%
Weighted average fair value per option	\$0.01	\$0.01

Expected annualized volatility was determined using the historic volatility of established comparable publicly traded companies.

Restricted Share Units ("RSUs")

A summary of restricted shares unit activity is as follows:

	Number of	Share price
	RSU's	on grant date
		\$
Balance at June 30, 2020	900,000	0.02
Granted	1,140,000	0.88
Exercised	(1,750,000)	
Balance at June 30, 2021	290,000	0.88
Granted	1,000,000	0.20
Balance at December 31, 2021	1,290,000	0.35

Share-based compensation expense recognized during the six months of \$172,473 related to Restricted Shares Units.

The following table summarizes RSU's outstanding and vested as of December 31, 2021:

Grant date	Number of RSUs	Number of Vested RSUs
April 5, 2021*	240,000	-
November 8, 2021	1,000,000	-
	1,240,000	

^{*240,000} RSUs vested on January 1, 2022.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Six months ended December 31, 2021

(Unaudited - Expressed in Canadian Dollars)

8. SHARE CAPITAL AND RESERVES (Continued)

Performance Stock Units ("PSUs")

During the six months ended December 31, 2021, the company granted 2,000,000 performance share units (the "PSUs") to a certain officer of the Company, each PSU representing the right to receive, once vested, and in accordance with the applicable PSU following award milestones, one common share in the capital of the Company. During the six months ended December 31, 2021, share-based compensation expense recognized was \$26,250 related to Performance Stock Units.

Milestones:

500,000 vested upon Company achieving \$3,500,000 in cumulative revenue; 500,000 vested upon Company achieving \$5,000,000 in cumulative revenue; 500,000 vested upon Company achieving \$7,500,000 in cumulative revenue; and 500,000 vested upon Company achieving \$10,000,000 in cumulative revenue.

Share Purchase Warrants

The Company enters into agreements for various services for which all or partial consideration is comprised of warrants. As the fair value of the provision of services is difficult to measure, the Company measures the fair value of services received or to be received by reference to the fair value of warrants granted using the Black-Scholes Model as described in the Company's Financial Statements.

A summary of warrant activity is as follows:

Number of	Weighted Average
Warrants	Exercise Price \$
16,504,033	0.56
(134,264)	0.60
16,369,769	0.56
4,000,000	0.60
(75,000)	0.45
20,294,769	0.57
	Warrants 16,504,033 (134,264) 16,369,769 4,000,000 (75,000)

The following table summarizes the warrants outstanding as of December 31, 2021:

	Number of	Weighted Average	Weighted Average
Expiry date	Warrants	Exercise Price \$	Remaining Years
August 18, 2022	3,512,500	0.45	0.63
August 28, 2022	275,000	0.45	0.66
September 2, 2022	500,000	0.45	0.67
September 18, 2022	50,000	0.45	0.72
September 30, 2022*	1,549,669	0.60	0.75
March 5, 2024	14,407,600	0.60	2.18
	20,294,769	0.57	1.74

^{**} Warrants relate to convertible promissory note (Note 9)

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Six months ended December 31, 2021

(Unaudited - Expressed in Canadian Dollars)

8. SHARE CAPITAL AND RESERVES (Continued)

A summary of broker warrants outstanding is as follows:

	Number of	Weighted Average
	Warrants	Exercise Price \$
Balance at June 30, 2021	1,400,000	0.30
Granted	480,000	0.50
Balance at December 31, 2021	1,880,000	0.35

The following table summarizes the broker warrants outstanding as of December 31, 2021:

	Number of	Weighted Average	Weighted Average
Expiry date	Warrants	Exercise Price \$	Remaining Years
March 5, 2024	1,400,000	0.30	2.18
March 5, 2024	480,000	0.50	2.18
	1,880,000	0.38	2.18

Each broker warrant is exercisable into units which consist of one common share and one-half common share purchase warrant exercisable until March 5, 2024. Upon conversion each full warrant shall be exercisable at a price of \$0.60 expiring on March 5, 2024.

9. CONVERTIBLE NOTES

On December 31, 2020, the Company completed a financing of Qualifying Convertible Notes in the aggregate Principal Amount of \$950,402. The Qualifying Convertible Notes automatically convert into Convertible Note Units upon the earlier of: (i) the Company receiving a receipt for its final Prospectus from the securities regulatory authorities in each of the jurisdictions in which the Company files the Prospectus; or (ii) the Maturity Date of the Qualifying Convertible Notes being March 31, 2021. Upon conversion, each Convertible Note Unit will be comprised of one Convertible Note Unit Share and one-half of one non-transferable Convertible Note Unit Warrant. Each whole Convertible Note Unit Warrant entitles the holder thereof to purchase one additional Convertible Note Unit Warrant Share at an exercise price of \$0.60 for a period of 24 months from the date of issuance. The Company did not receive any additional proceeds upon the automatic conversion of the Qualifying Convertible Notes upon the closing of its IPO. No commission or fee was paid by the Company with respect to the issue of the Qualifying Convertible Notes and no commission or fee was paid by the Company in connection with the issuance of the Convertible Note Units.

Upon closing of the IPO, the Qualifying Convertible Notes automatically converted into 3,183,083 units at a price of \$0.30 per share. Each unit consists of one common share and one half of one common share purchase warrant (1,591,533 warrants in total). Each full warrant is exercisable at a price of \$0.60 until December 31, 2022. Of the total shares issued, 3,167,993 related to the conversion of the principal balance 15,090 share were issued for \$4,527 in accrued interest.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

Six months ended December 31, 2021

(Unaudited - Expressed in Canadian Dollars)

10. RELATED PARTY TRANSACTIONS

Key management personnel

Key management personnel include those persons having authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of executive and non-executive members of the Company's Board of Directors and corporate officers and/or companies controlled by those individuals.

During the six months ended December 31, 2021, the Company entered the following key management transactions:

	C	December 31,	December 31
		2021	2020
Consulting services - David Kerbel, former CEO	\$	60,485 \$	33,400
Consulting services - Mike Hart, former President		-	22,500
Consulting services - Gurinder Sandhu, former Director		-	62,500
Consulting services - Amandeep Gill, former Director		-	62,500
Consuling services - Greg McCauley, former COO		75,606	-
Consulting services - Robert Payment, CFO		30,000	-
Consulting services - Company with common Director, Robert Payment		60,000	-
Salaries - Warren Spence, CEO and Director		36,000	-
Director Fees - Scott Eldridge, Director		25,000	-
Director Fees - David Lubotta, Director		25,000	-
Director Fees - Warren Spence, CEO and Director		25,000	-
Shares issued for services - David Kerbel, former CEO		-	20,000
Shares issued for services - Robert Payment, CFO		-	10,000
Shares issued for services - Warren Spence, CEO and Director		-	20,000
Shares issued for services - Gurinder Sandhu, former Director		-	40,000
Shares issued for services - Amandee Gill, former Director		-	40,000
Stock Based Compensation - David Kerbel, former CEO		11,090	537
Stock Based Compensation - Greg McCauley, former COO		26,102	-
Stock Based Compensation - Mike Hart, former President		-	537
Stock Based Compensation - Amadeep Gill, former Director		-	21,430
Stock Based Compensation - Gurinder Sandhu, former Director		-	21,430
Stock Based Compensation - Warren Spence, CEO		55,044	596
Stock Based Compensation - Robert Payment, CFO		26,102	9,877
Stock Based Compensation - Scott Eldridge, Director		42,773	6,276
Stock Based Compensation - David Lubotta, Director		41,772	537
al	\$	539,974 \$	372,120

Share-based compensation of \$202,883 (2020 - \$61,220) was related to directors, officers, and former directors and officers.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months ended December 31, 2021 (Unaudited - Expressed in Canadian Dollars)

11. FINANCIAL INSTRUMENTS

Fair value

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

- Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
- Level 3 Inputs that are not based on observable market data.

Cash is carried at fair value using a level 1 fair value measurement. The recorded values of receivables, accounts payable and accrued liabilities approximate their fair values due to their short-term to maturity.

Financial risk management

The Company may be exposed to risks of varying degrees of significance which could affect its ability to achieve its strategic objectives. The main objective of the Company's risk management processes are to ensure that risks are properly identified and that the capital base is adequate in relation to those risks. The principal risks to which the Company is exposed are described below.

Credit risk

Credit risk is the risk of potential loss associated with a counterparty's inability to fulfill its payment obligations. The Company's credit risk is primarily attributable to cash and trade receivables. Cash is held with reputable Canadian financial institutions, from which management believes the risk of loss is remote. As of December 31, 2021, the company had \$108,077 trade receivables with reputable US retailers all of which has been collected subsequent to quarter end. The Company's maximum credit risk exposure is equivalent to the carrying value of cash and the trade receivables.

Interest rate risk

Interest rate risk is the risk arising from the effect of changes in prevailing interest rates on the Company's financial instruments. The Company is exposed to interest rate risk to the extent that the cash maintained at the financial institutions is subject to a floating rate of interest. The interest rate risk on cash is not considered significant by management.

Liquidity risk

Liquidity risk is the risk that the Company is not able to meet its financial obligations as they fall due. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As of December 31, 2021, the Company's financial liabilities consist of accounts payable and accrued liabilities. Accounts payable and accrued liabilities have contractual maturities within one year. The Company manages liquidity risk by reviewing its capital requirements on an ongoing basis.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months ended December 31, 2021 (Unaudited - Expressed in Canadian Dollars)

11. FINANCIAL INSTRUMENTS (Continued)

Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign currency rates. An increase (decrease) of 10% in the foreign exchange rate between the USD and Canadian dollar will increase (decrease) net comprehensive income by \$25,394. The Company does not undertake currency hedging activities to mitigate its foreign currency risk.

12. CAPITAL MANAGEMENT

The Company defines capital as equity. The Company manages its capital structure and makes adjustments in order to have the funds available to support its operating activities.

The Company's objective when managing capital is to safeguard the Company's ability to continue as a going concern and to pursue the development of its business. The Company manages its capital structure and adjusts it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may issue new equity instruments, new debt, or acquire and/or dispose of assets. As discussed in Note 1, the Company's ability to continue as a going concern is uncertain and dependent upon the continued financial support of its shareholders, future profitable operations, and securing additional financing.

Management reviews its capital management approach on an ongoing basis. There were no changes in the Company's approach to capital management during the period presented. The Company is not subject to externally imposed capital requirement.

13. SEGMENTED INFORMATION

The Company operates in one reportable business segment, the marketing and distribution of dietary supplements containing functional mushrooms. The Company defines its reportable segments based on geographical locations — Canada, and USA. Reportable segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources, and in assessing performance. All sales during the period occurred in the United States.

Revenues from two of the Company's ecommerce platforms represent approximately 100% of the Company's total revenues.

14. COMMITMENTS AND CONTINGENCIES

Litigation Claim

On July 26, 2021, Force One Marketing Corporation and Force One Capital (together, "Force One"), filed a Statement of Claim against the Company in Ontario with respect to an alleged breach of a stock option agreement granting Force One 1,000,000 stock options exercisable at \$0.02. Force One alleges that it was a former consultant of the Company, and says the stock options were granted to it for capital raising and corporate advisory services. Force One is seeking an order for delivery of 1,000,000 Common Shares of the Company and general damages against the Company in the amount of \$3,500,000. The Company views the Force One's claim as largely devoid of merit and the Company will vigorously defend it. The Company has not yet filed a Statement of Defense and no court dates have been set.

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Six months ended December 31, 2021 (Unaudited - Expressed in Canadian Dollars)

14. COMMITMENTS AND CONTINGENCIES (continued)

Although management believes that the claim by Force One is without merit, defending the claim may be costly. If Force One's action is successful against the Company, it could result in the Company's business, operating results and financial condition being materially adversely affected.

Trademark Dispute

The Company received a letter from a natural health products company in the United States (the "Claimant") requesting the Company cease and desist from using the RRitual Trademark and the U.S. Trademark Application for "MENTAL FITNESS IS A DAILY RRITUAL" (Serial No. 90138515) on the basis of claims that it would cause consumer confusion with respect to products of the Claimant. Management is consulting with legal counsel regarding a response to the Claimant and intends to vigorously defend its intellectual property rights.

Although management believes that the trademark claims are without merit, the claims may be time-consuming and costly to defend and divert management's attention and resources away from the business. These claims of intellectual property infringement also might require Rritual to redesign affected products, enter into costly settlement or license agreements (if such licenses can be obtained on commercially reasonable terms, or at all) or pay costly damage awards, or face a temporary or permanent injunction prohibiting the marketing or selling certain of our products, which could result in the Company's business, operating results and financial condition being materially adversely affected.

15. SUBSEQUENT EVENT

Subsequent to December 31, 2021, the Company completed the following transactions:

- a) On February 7, 2022, the company entered into a shares exchange agreement (the "Agreement") with the shareholders of JustGo Juice Nutrition Ltd. ("JustGo"), a premium smoothie company, to acquire 100% of JustGo. Under the terms of the Agreement, and in consideration for the acquisition of JustGo, the Company has agreed to issue 33,000,000 shares to the JustGo shareholders.
 - At the time of issuance of these interim consolidated financial statements the draft results of this Company are yet to be determined due to the proximity of the issue date to the acquisition. It is thus impracticable to disclosure more detailed information for Purchase Price Allocation required at this time.
- b) On February 8, 2022, the Company announced that Greg McCauley has resigned as COO to pursue other opportunities.